GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » Interest Coverage

Nascent Biotech (Nascent Biotech) Interest Coverage : 0 (At Loss) (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Nascent Biotech's Operating Income for the three months ended in Dec. 2023 was $-0.36 Mil. Nascent Biotech's Interest Expense for the three months ended in Dec. 2023 was $-0.03 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Nascent Biotech's Interest Coverage or its related term are showing as below:


NBIO's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 145.09
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Nascent Biotech Interest Coverage Historical Data

The historical data trend for Nascent Biotech's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nascent Biotech Interest Coverage Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Interest Coverage
Get a 7-Day Free Trial No Debt - - - -

Nascent Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nascent Biotech's Interest Coverage

For the Biotechnology subindustry, Nascent Biotech's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Biotech's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nascent Biotech's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Nascent Biotech's Interest Coverage falls into.



Nascent Biotech Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Nascent Biotech's Interest Coverage for the fiscal year that ended in Mar. 2023 is calculated as

Here, for the fiscal year that ended in Mar. 2023, Nascent Biotech's Interest Expense was $-1.72 Mil. Its Operating Income was $-2.16 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Nascent Biotech did not have earnings to cover the interest expense.

Nascent Biotech's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Nascent Biotech's Interest Expense was $-0.03 Mil. Its Operating Income was $-0.36 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Nascent Biotech did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Nascent Biotech  (OTCPK:NBIO) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Nascent Biotech Interest Coverage Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Nascent Biotech (Nascent Biotech) Business Description

Traded in Other Exchanges
N/A
Address
631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is actively engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.
Executives
Lowell Thomas Holden director, officer: CFO 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick director, officer: President 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price director, officer: Senior VP Business Development 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas director 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy director, officer: CEO 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121